Equities

BioNexus Gene Lab Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BGLC:NAQ

BioNexus Gene Lab Corp

Actions
Basic MaterialsIndustrial Materials
  • Price (USD)2.20
  • Today's Change0.06 / 2.80%
  • Shares traded6.00
  • 1 Year change-40.70%
  • Beta2.3027
Data delayed at least 15 minutes, as of Feb 17 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2024202420232022
ASSETS
Cash And Short Term Investments1.582.620.61
Total Receivables, Net1.660.982.93
Total Inventory1.391.140.98
Prepaid expenses------
Other current assets, total2.793.311.51
Total current assets7.438.056.02
Property, plant & equipment, net1.741.651.57
Goodwill, net------
Intangibles, net------
Long term investments1.271.701.15
Note receivable - long term------
Other long term assets------
Total assets10118.74
LIABILITIES
Accounts payable1.501.401.86
Accrued expenses0.050.030.02
Notes payable/short-term debt000
Current portion long-term debt/capital leases----0
Other current liabilities, total0.400.190.13
Total current liabilities1.951.632.00
Total long term debt000
Total debt000
Deferred income tax00.010.03
Minority interest------
Other liabilities, total0.160.100.04
Total liabilities2.111.742.08
SHAREHOLDERS EQUITY
Common stock171711
Additional paid-in capital(5.01)(5.01)(5.01)
Retained earnings (accumulated deficit)(3.44)(1.84)1.16
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.56)(0.68)(0.41)
Total equity8.329.666.67
Total liabilities & shareholders' equity10118.74
Total common shares outstanding1.801.771.45
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.